Glucose-6-phosphate isomerase is associated with disease activity and declines in response to infliximab treatment in rheumatoid arthritis  

作　　者：Jing Xu Xiao-Ying Zhang Ru Li Jing Liu Hua Ye Xue-Wu Zhang Zhan-Guo Li 

机构地区：[1]Department of Rheumatology and Immunology,Peking University People’s Hospital,Beijing 100044,China [2]Department of Rheumatology and Immunology,Peking University International Hospital,Beijing 102206,China [3]Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis(BZ0135),Beijing 100044,China

出　　处：《Chinese Medical Journal》2020年第8期886-891,共6页中华医学杂志（英文版）

基　　金：This study was supported by grants from the National Natural Science and Foundation of China(Nos.81701598 and 31240023);Beijing Municipal Science and Technology Project(No.Z171100000417007)。

摘　　要：Background:Rheumatoid arthritis (RA), a systemic autoimmune disease characterized by synovial inflammation, can cause cartilage and bone damage as well as disability. The aim of this study was to explore whether serum glucose-6-phosphate isomerase (GPI) is correlated with disease activity and the value of GPI in the evaluation of infliximab treatment in patients with RA.Methods:Sixty-two patients with RA who had an inadequate response to methotrexate (MTX) were enrolled in Peking University People’s Hospital from July 1, 2016 to July 31, 2018. Infliximab (3 mg/kg, intravenous at weeks 0, 2, and 6 and then every 8 weeks) was administered to patients with stable background MTX therapy. Serum samples were obtained at baseline and week 18. Serum GPI levels were determined using enzyme-linked immunosorbent assay. The associations between serum GPI levels and clinical features were analyzed.Results:Serum GPI was positively correlated with Disease Activity Score in 28 joints (DAS28), swollen joint count, tender joint count and C-reactive protein level ( P < 0.001, P < 0.001, P < 0.001, and P = 0.033, respectively). The change of DAS28 in GPI-positive patients was greater than that in GPI-negative patients ( P < 0.001). Compared with those for patients receiving MTX monotherapy at baseline, the GPI levels were significantly declined when MTX was combined with infliximab ( P < 0.001). Conclusion:Serum GPI is related to disease activity and clinical response to infliximab treatment.

关 键 词：Glucose-6-phosphate isomerase Rheumatoid arthritis TREATMENT 

分 类 号：R593.22[医药卫生—内科学]